Related Experiment Video
Updated: Mar 30, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia]
Rui Guo1, An-Li Shen1, Yan Wang1
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing 210029, Jiangsu Province, China.
Insights
CD56 positive acute myeloid leukemia (AML) occurs in 24.27% of patients. While CD56⁺ AML often indicates a poor prognosis, further research is needed for cases with additional antigen expressions.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- CD56 expression is an uncommon immunophenotypic marker in AML.
- Understanding CD56 expression patterns is crucial for AML subtyping and prognosis.
Purpose of the Study:
- To investigate the immunophenotypic characteristics of newly diagnosed CD56-positive acute myeloid leukemia (AML).
- To analyze the association of CD56 expression with other immunophenotypic markers in AML patients.
Main Methods:
- A cohort of 342 AML patients was analyzed using four-color flow cytometry and cytomorphology.
- Immunophenotypic analysis focused on CD56 expression and its correlation with other cell surface markers.
Main Results:
- CD56 expression was identified in 24.27% (83/342) of AML patients, predominantly in subtypes M1, M2, M5, and M6.
- A statistically significant difference was observed between CD56⁺ and CD11b⁺ AML (P < 0.05).
- No significant statistical differences were found between CD56⁺ AML and other common AML markers (e.g., HLA-DR, CD34, CD33).
Conclusions:
- CD56 positivity in AML is associated with specific subtypes and a distinct immunophenotype.
- AML exclusively expressing CD56 generally carries a poor prognosis.
- The prognostic implications of CD56⁺ AML with co-expressed antigens require further investigation.
Objective:
To explore the immunophenotype characteristics of newly diagnosed patients with CD56⁺ acute myeloid leukemia (AML).
Methods:
Combining with cytomorphology, four-color flow cytometry was used to analyze the immunophenotype of 342 AML patients with CD56⁺ or CD56⁻.
Results:
In 342 AML patients, the CD56⁺ expression was found in 83 AML patients who accounted for 24.27% and included 10 cases of M1, 45 cases of M2, 5 cases of M3, 6 cases of M6 and 17 cases of M5. The statistical analysis showed that there was statistical difference between CD56⁺ and CD11b⁺ patients (P < 0.05), but there was no statistical difference between CD56⁺ and HLA-DR, CD34, CD38, CD13, CD33, CD15, CD117, CD14, CD64, CD2, CD7, CD5, CD3, CD4, CD10, CD19, CD20, CD22 (P > 0.05).
Conclusion:
AML with only CD56 positive always has poor prognosis, thus the prognosis of patients with CD56⁺ AML accompanied by other antigens still needs more research.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025